0000000000064107

AUTHOR

Simona Delle Monache

0000-0002-8153-915x

showing 2 related works from this author

Extremely low frequency electromagnetic fields (ELF-EMFs) induce in vitro angiogenesis process in human endothelial cells.

2008

Effects of extremely low frequency (ELF) electromagnetic fields (EMFs) on activation of angiogenesis were analysed using cultured umbilical human vein endothelial cells (HUVECs). The cultures were exposed to a sinusoidal EMF to intensity of 1 mT, 50 Hz for up to 12 h. EMFs increased the degree of endothelial cell proliferation and tubule formation, coupled by an acceleration in the process of wound healing. Since this process is physiologically accompanied by a large modification in the structural organization of actin and focal adhesions, we analyzed the rearrangement of some cytoskeleton elements demonstrating a major reorganization of the fibres and of the focal adhesion complexes after …

animal structuresCytoskeleton organizationPhysiologyAngiogenesisBiophysicsNeovascularization PhysiologicBiologyRadiation DosageFocal adhesionElectromagnetic FieldsEndothelial cellElectricityHumansRadiology Nuclear Medicine and imagingTherapeutic angiogenesisCytoskeletonCells CulturedEndothelial CellsDose-Response Relationship RadiationGeneral MedicineCell biologyEndothelial stem cellAngiogenesiSignal transductionWound healingExtremely low frequency electromagnetic fieldsBioelectromagnetics
researchProduct

Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter “SLAVE” S…

2020

: Background: The optimal anti-angiogenic strategy as second-line treatment in RAS wild-type metastatic colorectal cancer (mCRC) treated with anti-EGFR (Epidermal Growth Factor Receptor) based first-line treatment is still debated. Methods: This multicenter, real-world, retrospective study is aimed at evaluating the effectiveness of second-line Bevacizumab- and Aflibercept-based treatments after an anti-EGFR based first-line regimen. Clinical outcomes measured were: objective response rate (ORR), progression free survival (PFS), overall survival (OS) and adverse events (AEs) profiles. Results: From February 2011 to October 2019, 277 consecutive mCRC patients received Bevacizumab-based (228,…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyBevacizumabColorectal cancerAnti-angiogenicCetuximablcsh:RC254-282Article03 medical and health sciences0302 clinical medicineInternal medicinemedicinePanitumumabProgression-free survivalAfliberceptRAS wild-type mCRCPerformance statusCetuximabbusiness.industryPanitumumabanti-angiogenicsmedicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensBevacizumabRegimen030104 developmental biologyOncology030220 oncology & carcinogenesissecond-line treatmentbusinessAfliberceptaflibercept; anti-angiogenics; bevacizumab; cetuximab; panitumumab; ras wild-type mcrc; second-line treatmentmedicine.drugCancers
researchProduct